Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib consolidation before treatment-free remission in chronic myeloid leukemia
2017-004565-27Phase 2Active
- Sponsor
- Fundación Teófilo Hernando
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in chronic myelogenous leukemia (CML), sponsored by Fundación Teófilo Hernando. Primary endpoint: Primary efficacy endpoint. Started Sep 2018; status: active.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2017-004565-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004565-27.